Advanced in Ewing Sarcoma
Advanced in Ewing Sarcoma
2801 N Gantenbein Ave, 
Portland, OR 
 (146.9 mi)

Overview

Janice Olson is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Portland, Oregon. Dr. Olson has been practicing medicine for over 40 years and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Hepatoblastoma, Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration. Dr. Olson is currently accepting new patients.

Her clinical research consists of co-authoring 1 peer reviewed article and participating in 66 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 15 clinical trials in the study of Ewing Sarcoma.

Graduate Year
1985
Specialties
Pediatric Hematology Oncology
Pediatrics
Licenses
Pediatric Hematology-Oncology in OR
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  BridgeSpan
  •  PacificSource
  •  Regence
  •  Prominence Health

Locations

2801 N Gantenbein Ave, Portland, OR 97227

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


66 Clinical Trials

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 43 Less Clinical Trials
Similar Doctors
Distinguished in Ewing Sarcoma
Oncology | Pediatric Hematology Oncology | Pediatrics
Distinguished in Ewing Sarcoma
Oncology | Pediatric Hematology Oncology | Pediatrics

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (3.2 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Lara Davis is an Oncologist and a Pediatric Hematologist Oncology provider in Portland, Oregon. Dr. Davis and is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Epithelioid Sarcoma, Rhabdomyosarcoma Embryonal, Alveolar Soft Part Sarcoma, and Mesenchymoma. Dr. Davis is currently accepting new patients.

Advanced in Ewing Sarcoma
Pediatric Hematology Oncology | Pediatrics | Hematology
Advanced in Ewing Sarcoma
Pediatric Hematology Oncology | Pediatrics | Hematology
3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (3.2 mi)
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Matthew Dietz is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Portland, Oregon. Dr. Dietz and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration. Dr. Dietz is currently accepting new patients.

Advanced in Ewing Sarcoma
Pediatric Hematology Oncology | Pediatrics
Advanced in Ewing Sarcoma
Pediatric Hematology Oncology | Pediatrics

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (3.2 mi)
Languages Spoken:
English
Accepting New Patients

Katrina Winsnes is a Pediatric Hematologist Oncology specialist and a Pediatrics provider in Portland, Oregon. Dr. Winsnes and is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Winsnes is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile